Truist Financial Issues Pessimistic Forecast for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its price target reduced by equities research analysts at Truist Financial from $62.00 to $57.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price would suggest a potential upside of 26.51% from the company’s current price.

BSX has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Canaccord Genuity Group set a $66.00 price target on Boston Scientific in a research note on Thursday. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Citigroup reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $74.50.

Boston Scientific Trading Down 2.1%

NYSE:BSX traded down $0.98 on Thursday, hitting $45.06. 5,595,767 shares of the stock were exchanged, compared to its average volume of 18,234,096. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific has a 52 week low of $42.20 and a 52 week high of $109.50. The stock has a market capitalization of $66.97 billion, a price-to-earnings ratio of 18.86, a P/E/G ratio of 0.88 and a beta of 0.58. The company’s 50-day moving average price is $46.57 and its 200 day moving average price is $62.73.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same quarter last year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific will post 3.35 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Outfitters Financial LLC increased its holdings in shares of Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after acquiring an additional 110 shares in the last quarter. Natural Investments LLC grew its position in shares of Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after purchasing an additional 112 shares during the period. Patton Fund Management Inc. grew its position in shares of Boston Scientific by 5.5% in the 4th quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 118 shares during the period. Bridgewater Advisors Inc. increased its stake in Boston Scientific by 1.2% during the 4th quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider’s stock worth $921,000 after purchasing an additional 123 shares in the last quarter. Finally, Earned Wealth Advisors LLC increased its stake in Boston Scientific by 5.2% during the 4th quarter. Earned Wealth Advisors LLC now owns 2,647 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 131 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q2 results exceeded expectations: Boston Scientific reported adjusted EPS of $0.86 versus the $0.83 consensus estimate, while revenue rose 7.5% year over year to $5.442 billion, above the $5.37 billion forecast. Cardiovascular sales increased 8.3%, with particularly strong growth in APAC and LACA. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Growth and cost initiatives remain longer-term catalysts: Management highlighted broad portfolio growth, new product launches, cost savings from its restructuring program, FDA clearance for the TruSelect 2.6 Microcatheter, and the company’s investment in MiRus and its transcatheter aortic valve replacement business. The restructuring targets approximately $500 million in annual savings, although it may cost $700 million to $800 million through 2029. Boston Scientific Q2 earnings call highlights
• Neutral Sentiment: Sales outlook was raised, but profit expectations were reduced: Boston Scientific now expects full-year reported sales growth of approximately 5.5% to 6.5%, but cut adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41. Third-quarter EPS guidance of $0.80-$0.82 and revenue guidance of $5.2-$5.3 billion also trail consensus estimates of $0.84 and $5.4 billion, respectively. Boston Scientific trims annual profit forecast
• Negative Sentiment: Watchman and EP weakness is resetting expectations: Softer demand for the Watchman device, competitive pressure and weaker trends in EP are forcing management to take a more cautious view of growth. Analysts have responded by cutting valuation targets, including UBS’s reduction to $74 from $95, BTIG’s reduction to $60 from $65, and a fair-value cut to $72.25 from $75. BSX Q2 earnings call highlights WATCHMAN and EP pressure
• Negative Sentiment: Restructuring and recall add execution risk: The multi-year restructuring will involve headcount reductions and significant upfront costs, while a recall of the Rapid Refill Continuous Injection System creates an additional operational and reputational concern. Boston Scientific expects headcount reductions

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.